Catalog4 refs
Pancragen (KEDW)
MetabolicResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Overview
Pancragen is a Khavinson bioregulator tetrapeptide (KEDW) originally isolated from bovine pancreatic cells. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it directly interacts with DNA to regulate pancreatic gene expression. Research in old rhesus monkeys demonstrated that Pancragen corrected impaired glucose tolerance, normalized insulin and C-peptide levels, and improved endocrine pancreatic function. It is considered safe and effective for age-related metabolic disturbances.
Primary Uses
Corrects impaired glucose tolerance
Normalizes insulin levels
Normalizes C-peptide levels
Improves endocrine pancreatic function
Supports pancreatic cell differentiation
Regulates melatonin expression
Reduces metabolic syndrome incidence
Upregulates key pancreatic transcription factors
Blood sugar regulation
Age-related pancreatic decline
Gene expression regulation
Protocol Reference
Dose
10-20 mg daily
Frequency
Daily for 10-20 days per cycle; 2-3 cycles yearly for maintenance
Half-life
Not established
Route
Oral capsules · Injectable
Evidence
Moderate Research
Research Models
bovine (source)rhesus monkeys
Also in Metabolic